**PRODUCT NEWS**

**MitraClip Now Helps Many More with Secondary Mitral Regurgitation**

The U.S. Food and Drug Administration approved a new, expanded indication for our leading MitraClip device. Supported by the results of the landmark COAPT Trial, MitraClip is the only mitral device approved to treat advanced heart failure patients with significant secondary mitral regurgitation. Read more here.

**Alinity Selected by Regional Medical Laboratory, Inc.**

Regional Medical Laboratory, Inc. (RML) will use our most advanced technology, Alinity ci-series, to conduct diagnostic tests for millions of patients. RML, part of the Ascension network – which is the largest non-profit health system in the U.S., performs diagnostics testing for more than 2.4 million patients through hospital systems in Texas, Wisconsin, Oklahoma, Kansas and Tennessee. Read more here.

**STRATEGY SPOTLIGHT**

**Built for Success Today and Tomorrow**

Our Chairman and CEO Miles D. White spoke to Forbes’ Bruce Rogers about his influences and insights in building and shaping the company for success today – and for sustainable growth tomorrow. Read more here.

**A Better Way to Manage Diabetes, Insulin**

Our partnership with Novo Nordisk is an exciting development reflecting our commitment to making diabetes management easier by connecting key technologies such as continuous glucose monitoring and connected insulin pens. Read more here.

**INNOVATION**

**New Breakthroughs in Cardiovascular Care**

Last week, Abbott and our research partners delivered five impressive late-breaking data presentations at the American College of Cardiology’s 68th Annual Scientific Session. The data showed exciting results for our key cardiovascular technologies – the MitraClip system for transcatheter mitral valve repair, the HeartMate 3 heart pump, the CardioMEMS HF System for proactive heart failure monitoring, and the XIENCE drug eluting coronary stent. Learn more here.

**HEALTH TECHNOLOGY**

**Improving Health Through Better Data**

From heart disease to cancer predictions to understanding hard-to-diagnose mild traumatic brain injury, the major medical problems in all markets are already being changed by AI and the potential from data analysis. Learn more about what Abbott had to say at The Wall Street Journal’s Tech Health conference in San Francisco. Read more here.

For the latest on what’s happening at Abbott, visit us at www.abbottinvestor.com or follow us on Twitter and LinkedIn.